Xilio Development Inc (XLO) - Net Assets
Based on the latest financial reports, Xilio Development Inc (XLO) has net assets worth $-8.10 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($133.69 Million) and total liabilities ($141.79 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read total liabilities of Xilio Development Inc for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-8.10 Million |
| % of Total Assets | -6.05% |
| Annual Growth Rate | -14.49% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 27.25 |
Xilio Development Inc - Net Assets Trend (2019–2024)
This chart illustrates how Xilio Development Inc's net assets have evolved over time, based on quarterly financial data. Also explore Xilio Development Inc total assets for the complete picture of this company's asset base.
Annual Net Assets for Xilio Development Inc (2019–2024)
The table below shows the annual net assets of Xilio Development Inc from 2019 to 2024. For live valuation and market cap data, see Xilio Development Inc (XLO) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $17.60 Million | -52.21% |
| 2023-12-31 | $36.83 Million | -65.14% |
| 2022-12-31 | $105.65 Million | -43.03% |
| 2021-12-31 | $185.43 Million | +3608.59% |
| 2020-12-31 | $-5.29 Million | -113.72% |
| 2019-12-31 | $38.51 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Xilio Development Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 35388600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.00K | 0.03% |
| Other Components | $401.35 Million | 2280.63% |
| Total Equity | $17.60 Million | 100.00% |
Xilio Development Inc Competitors by Market Cap
The table below lists competitors of Xilio Development Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Planet Image International Limited Class A Ordinary Shares
NASDAQ:YIBO
|
$36.87 Million |
|
dMY Squared Technology Group Inc
NYSE MKT:DMYY
|
$36.88 Million |
|
Dongil Technology Ltd
KQ:032960
|
$36.92 Million |
|
Australian Mines Ltd
AU:AUZ
|
$36.93 Million |
|
Xiabuxiabu Catering Management (China) Holdings Co. Ltd
F:0XI
|
$36.86 Million |
|
Hidropar Hareket Kontrol Teknolojileri Merkezi Sanayi ve Ticaret A.S.
IS:HKTM
|
$36.83 Million |
|
Drax Group PLC
LSE:DRX
|
$36.82 Million |
|
Medicenna Therapeutics Corp
TO:MDNA
|
$36.81 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Xilio Development Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 36,827,000 to 17,598,000, a change of -19,229,000 (-52.2%).
- Net loss of 58,241,000 reduced equity.
- New share issuances of 6,825,000 increased equity.
- Other factors increased equity by 32,187,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-58.24 Million | -330.95% |
| Share Issuances | $6.83 Million | +38.78% |
| Other Changes | $32.19 Million | +182.9% |
| Total Change | $- | -52.21% |
Book Value vs Market Value Analysis
This analysis compares Xilio Development Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 25.30x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 59.35x to 25.30x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $0.14 | $8.32 | x |
| 2020-12-31 | $-0.19 | $8.32 | x |
| 2021-12-31 | $6.78 | $8.32 | x |
| 2022-12-31 | $3.86 | $8.32 | x |
| 2023-12-31 | $1.34 | $8.32 | x |
| 2024-12-31 | $0.33 | $8.32 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Xilio Development Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -330.95%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -918.05%
- • Asset Turnover: 0.09x
- • Equity Multiplier: 4.04x
- Recent ROE (-330.95%) is below the historical average (-117.68%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -44.95% | 0.00% | 0.00x | 1.63x | $-21.16 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-54.69 Million |
| 2021 | -40.07% | 0.00% | 0.00x | 1.20x | $-92.84 Million |
| 2022 | -82.63% | 0.00% | 0.00x | 1.32x | $-97.86 Million |
| 2023 | -207.47% | 0.00% | 0.00x | 1.65x | $-80.09 Million |
| 2024 | -330.95% | -918.05% | 0.09x | 4.04x | $-60.00 Million |
Industry Comparison
This section compares Xilio Development Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Xilio Development Inc (XLO) | $-8.10 Million | -44.95% | N/A | $36.86 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Xilio Development Inc
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which compr… Read more